Is VIP the same as a neurotransmitter?

VIP functions as both a neurotransmitter and a hormone. It's released by neurons in the nervous system and also circulates in the blood as a hormone-like signal. This dual role is part of what makes it scientifically interesting and therapeutically complex.

Why hasn't VIP been approved by the FDA if it's been studied for decades?

Despite promising preclinical data, clinical trials have not demonstrated efficacy large enough to meet regulatory approval standards. Peptide therapeutics also face bioavailability, stability, and immunogenicity challenges that have delayed translation for many compounds in this class.

Can I use VIP outside of a clinical trial?

VIP is investigational and not approved for clinical use in the US, EU, or Canada. It may be available through research compound sources, but these operate outside regulatory oversight—meaning quality and safety cannot be guaranteed. Clinical trial participation is the most rigorous pathway.

What's the difference between VIP and other peptides like Alexamorelin?

[Alexamorelin](/compounds/alexamorelin) is a growth hormone secretagogue with different mechanisms and applications than VIP. VIP focuses on immunomodulation and neuroinflammation, while Alexamorelin targets growth hormone secretion. Each has distinct trial profiles and mechanisms.

Are there any peptides similar to VIP that are already approved?

Most immunomodulatory peptides remain investigational. Approved therapeutics in inflammatory and autoimmune spaces typically use small molecules, monoclonal antibodies, or biologics rather than neuropeptides like VIP. This reflects the manufacturing and bioavailability hurdles peptides face.

VIP Complete Guide: What You Need to Know

VIP (Vasoactive Intestinal Peptide) is a research-stage neuropeptide that functions as both a neurotransmitter and hormone in the human body. Unlike approved therapeutics, VIP remains investigational with 121 active clinical trials exploring its potential across multiple biological systems. Research indicates it plays critical roles in immune regulation, neuroinflammation, and vasodilation, making it one of the most studied peptides in the research landscape. This guide covers everything from its discovery to current trial activity, regulatory status, and what the emerging research actually shows.

What Is VIP?

Vasoactive Intestinal Peptide (VIP) is a 28-amino acid neuropeptide discovered in the 1970s. It was first identified in the intestines—hence the name—but subsequent research revealed it's distributed throughout the nervous system, immune cells, and endocrine tissues. VIP acts as a signaling molecule, binding to specific receptors (VPAC1 and VPAC2) on cell surfaces to trigger a cascade of biological responses.

What makes VIP scientifically compelling is its dual nature. Research indicates it functions simultaneously as a neurotransmitter in the central and peripheral nervous systems and as a circulating hormone. This versatility explains why it appears in trials spanning neurology, immunology, and gastroenterology.

The Mechanism: How VIP Works at the Cellular Level

VIP's biological activity centers on receptor activation and intracellular signaling. When VIP binds to VPAC1 or VPAC2 receptors, it activates a cAMP-dependent pathway—a fundamental cellular communication system. This activation cascade influences gene expression, enzyme activity, and cellular behavior across multiple tissue types.

Immune Regulation

One of VIP's most researched properties is its immunomodulatory effect. Preclinical studies demonstrate that VIP can shift immune responses toward anti-inflammatory patterns. It suppresses pro-inflammatory cytokines like TNF-alpha and IL-6 while promoting regulatory T cell populations. This mechanism has generated interest in inflammatory and autoimmune conditions, though clinical translation remains early.

Neuroinflammation and Neuroprotection

Animal studies suggest VIP crosses the blood-brain barrier and may modulate microglial activation—the brain's resident immune cells. Research in animal models shows VIP reduces neuroinflammatory markers and provides neuroprotective effects in injury and degeneration scenarios. Whether this translates to clinical benefit in humans is precisely what the 121 ongoing trials are investigating.

Vasodilation and Vascular Function

True to its name, VIP is a potent vasodilator. It relaxes vascular smooth muscle, increasing blood flow and reducing vascular resistance. This property was documented early in VIP research and remains clinically relevant for cardiovascular and pulmonary applications.

Current Clinical Trial Landscape

With 121 registered clinical trials, VIP is among the most actively investigated peptides globally. These trials span a broad range of indications:

Neurological conditions: Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis (ALS), and traumatic brain injury
Inflammatory/autoimmune: Crohn's disease, ulcerative colitis, rheumatoid arthritis, and systemic lupus erythematosus
Pulmonary: Pulmonary hypertension, acute respiratory distress syndrome (ARDS), and interstitial lung disease
Other: Gastrointestinal motility disorders, sepsis, and post-COVID syndrome

The sheer volume of trial activity reflects genuine scientific interest but also reflects that VIP's clinical utility remains unproven. None of these trials has yet produced Phase III data strong enough for regulatory approval in major markets.

Research Evidence: What We Know and Don't Know

Preclinical Evidence (Animal Studies)

Animal research on VIP is robust. Murine and primate models consistently show beneficial effects in inflammatory, infectious, and neurodegenerative scenarios. However, there's a critical caveat: animal models don't always predict human outcomes. The jump from mouse to human efficacy is historically unpredictable.

Human Trial Data

Human trials have produced mixed results. Early Phase II studies suggested potential in some inflammatory conditions, but larger Phase II and Phase III trials have generally failed to meet primary endpoints or showed modest effects requiring statistical hedging. This is typical for peptide-based therapeutics, which face challenges in bioavailability, stability, and immunogenicity.

Safety Profile in Humans

Across available trial data, VIP has generally shown a favorable safety profile in short-term dosing. Reported adverse events tend to be mild: headache, flushing, injection-site reactions, and transient gastrointestinal symptoms. Serious adverse events have been rare in published trials. However, long-term safety data in humans remains limited, and VIP's systemic immunomodulatory effects theoretically carry risks (e.g., immunosuppression, infection susceptibility) that require careful monitoring.

Regulatory Status: Why VIP Isn't Approved Yet

VIP holds investigational status in the United States, European Union, and Canada. It is not approved by the FDA, not authorised by the EMA, and not approved by Health Canada.

Why? Despite decades of research and promising mechanisms, VIP has not cleared the regulatory bar for approval. This typically reflects one or more of the following:

Efficacy gaps: Trials have not demonstrated clinical benefit large enough to justify approval relative to existing treatments.
Manufacturing challenges: Peptides are complex molecules requiring careful manufacturing, stability testing, and quality control. Ensuring consistent pharmaceutical peptides involves sophisticated accelerated stability testing and formulation work.
Bioavailability: VIP is a peptide, meaning it's susceptible to enzymatic degradation in the gut and blood. Oral delivery is impractical; injections are required. This limits market appeal.
Immunogenicity: Repeated peptide dosing can trigger immune responses, reducing efficacy over time. Managing this remains an unsolved problem for many peptide therapeutics.

VIP's investigational status means it is available only in clinical trial settings in regulated markets. In some jurisdictions, it may be available through research compounds channels, but this falls outside regulatory oversight and carries inherent risks around quality, purity, and potency.

VIP vs. Related Compounds

If you're exploring neuropeptide research, VIP sits alongside other investigational compounds worth understanding:

Alexamorelin: A growth hormone secretagogue with different mechanisms and trial profile than VIP.
ARA-290: Another immunomodulatory peptide with distinct receptor targets, currently in trials for neuropathy and inflammation.
ACE-031: A myostatin inhibitor focused on muscle biology rather than immune regulation.

Each represents different research trajectories within peptide science.

Safety Considerations and Known Risks

VIP's safety profile in humans appears favorable based on available trial data, but several caveats apply:

Short-Term vs. Long-Term Safety

Most VIP trials are relatively short (weeks to months). Long-term safety—particularly regarding immune tolerance, antibody formation, and cumulative effects—remains understudied in humans.

Immunomodulation Risks

VIP's immunosuppressive effects, beneficial in inflammatory conditions, could theoretically increase infection risk or unmask latent infections in susceptible individuals. This requires careful patient selection and monitoring in any clinical use.

Injection-Related Issues

As a peptide requiring injection, VIP carries standard risks: infection, abscess formation, and patient discomfort. Route, frequency, and formulation all affect safety.

Peptide-Specific Challenges

Peptides can trigger neutralizing antibodies with repeated dosing, reducing efficacy or causing allergic reactions. VIP's immunogenicity remains an active area of investigation.

The Current Research Frontier

Active research is exploring:

Optimized formulations: Delivery systems (liposomes, nanoparticles) to improve VIP stability and target specific tissues.
Combination therapies: Pairing VIP with other immunomodulators or anti-inflammatories.
Patient stratification: Identifying which patients are most likely to benefit based on biomarkers or genetic factors.
Novel indications: Emerging interest in post-COVID syndrome and long-COVID research, driven by VIP's immunomodulatory and neuroinflammatory properties.

The 121 clinical trials represent genuine scientific momentum, but they also underscore that VIP remains firmly in the investigational phase. Meaningful regulatory approval would require Phase III trials demonstrating superiority or non-inferiority to existing treatments—a hurdle VIP has not yet cleared.

Sourcing and Availability

VIP is available exclusively through clinical trial participation in regulated markets. Outside clinical trials, VIP may be marketed as a research compound, but such material operates outside FDA, EMA, and Health Canada oversight. Quality, purity, potency, and safety cannot be assured for research compound supply. This carries inherent risks for anyone considering use outside approved clinical contexts.

If you're interested in VIP research, clinical trial enrollment remains the safest and most scientifically rigorous pathway.

Key Takeaways

VIP is a 28-amino acid neuropeptide with dual roles as neurotransmitter and hormone.
It operates via VPAC receptors, triggering cAMP-dependent signaling affecting immune function, neuroinflammation, and vasodilation.
121 clinical trials are exploring applications in neurology, immunology, and pulmonology—reflecting genuine scientific interest.
Despite decades of research, VIP has not achieved regulatory approval in the US, EU, or Canada due to efficacy gaps, bioavailability challenges, and manufacturing complexity.
Safety data from human trials are generally favorable for short-term use, but long-term safety remains understudied.
VIP is available only through clinical trials in regulated markets; research compound sources operate without regulatory oversight.

VIP: The Complete Guide to Vasoactive Intestinal Peptide